Introduction
Patient selection
Data collection and definitions
Statistical analysis
Results
Patient characteristics, prior treatment, and transplantation procedures details
Characteristics at diagnosis | Number (%) |
---|---|
Total number of pts | 65 (100) |
Age (years), median 42, range 15–64 | |
≤60 years | 61 (94) |
>60 years | 4 (6) |
Gender | |
Male | 32 (49) |
Female | 33 (51) |
Histology | |
PTCL not otherwise specified | 36 (55) |
AITL | 9 (14) |
ALCL | 20 (31) |
ALK-negative | 7 (11) |
ALK-positive | 4 (6) |
ALK-unknown | 9 (14) |
Ann Arbor stage | |
I–II | 14 (21.5) |
III–IV | 50 (77) |
Unknown | 1 (1.5) |
Constitutional symptoms | |
Absent | 14 (21.5) |
Present | 51 (78.5) |
BM involvement | |
No | 44 (68) |
Yes | 16 (24.5) |
Unknown | 5 (7.5) |
IPI score | |
0–1 | 16 (25) |
2 | 17 (26) |
3–4 | 24 (37) |
Unknown | 8 (12) |
PIT score | |
0 | 10 (15) |
1 | 23 (35) |
2–3 | 18 (28) |
Unknown | 14 (22) |
Treatment details | Number (%) |
---|---|
Induction chemotherapy | |
CHOP | 57 (88) |
CHOP and etoposide | 2 (3) |
Others anthracycline-containing combination chemotherapies | 6 (9) |
Response after induction chemotherapy | |
CR | 12 (18) |
PR | 41 (64) |
Primary refractorinessa
| 12 (18) |
Second-line chemotherapy | 46 (71) |
ESHAP or DHAP | 27 (42) |
Other platinum-containing regimen | 4 (6) |
Others | 15 (23) |
Number of pre-transplant regimens | |
1 | 18 (28) |
2 | 42 (65) |
>2 | 5 (7) |
Disease status at autoHSCT | |
CR | 36 (55) |
PR | 29 (45) |
Autologous graft source | |
Mobilized peripheral blood | 62 (95) |
Bone marrow | 3 (5) |
The number of infused CD34 positive cells ×106/kg | |
Median | 5.6 |
Range | 1.6–22.8 |
Conditioning regimen | |
BEAM | 38 (58) |
CBV | 18 (28) |
CyTBI | 3 (5) |
Others | 6 (9) |
Posttransplantation outcomes
Group | No. | 5-year OS (95 % CI) |
p value | 5-year PFS (95 %) |
p value |
---|---|---|---|---|---|
Ann Arbor stage | |||||
I–II | 14 | 84.6 (57.8–95.7) | 0.099 | 78.6 (52.3–92.5) | 0.10 |
III–IV | 50 | 53.0 (36.5–68.8) | 52.1 (36.8–67.0) | ||
B symptoms at diagnosis | |||||
No | 14 | 83.3 (55.1–95.3) | 0.066 | 85.1 (58.8–95.8) | 0.023 |
Yes | 51 | 53.8 (37.3–69.5) | 51.5 (36.6–66.2) | ||
Bone marrow involvement at diagnosis | |||||
No | 44 | 69.2 (50.9–82.9) | 0.004 | 69.9 (53.7–82.3) | 0.002 |
Yes | 16 | 34.9 (15.1–61.9) | 24.1 (8.8–51.1) | ||
Response to induction regimen | |||||
≥PR | 53 | 66.0 (49.9–79.1) | 0.050 | 65.2 (50.0–77.8) | 0.004 |
Primary refractorinessa
| 12 | 41.0 (16.6–70.9) | 33.3 (6.6–60.0) | ||
Disease status at transplant | |||||
CR | 36 | 65.7 (46.9–80.6) | 0.46 | 64.5 (46.3–79.3) | 0.23 |
less than CR | 29 | 57.1 (35.5–76.3) | 54.7 (36.5–72.9) | ||
Number of prior chemotherapy regimen | |||||
1 | 19 | 77.2 (53.7–90.7) | 0.17 | 78.7 (56.6–90.8) | 0.08 |
2 or more | 46 | 56.8 (40.7–71.6) | 51.7 (36.9–66.2) | ||
Histology | |||||
ALK-positive and ALK-unknown ALCL | 13 | 54.2 (26.2–79.8) | 0.70 | 59.8 (33.4–81.5) | 0.89 |
Other types | 52 | 63.3 (47.1–77.0) | 59.3 (44.4–72.6) | ||
ALCL-all subtypes | 20 | 63.6 (38.8–82.8) | 0.77 | 63.8 (41.7–81.3) | 0.70 |
PTCL-NOS and AITL | 45 | 60.7 (43.4–75.7) | 57.5 (41.5–72.1) | ||
ALK-positive and ALK-unknown ALCL | 13 | 54.2 (26.2–79.8) | 0.74 | 59.8 (33.4–81.5) | 0.62 |
ALK-negative ALCL | 7 | 83.3 (43.7–97.0) | 71.4 (35.8–91.8) | ||
PTCL-NOS | 36 | 60.7 (42.3–76.5) | 55.8 (39.0–71.3) | ||
AITL | 9 | 55.6 (18.0–87.7) | 55.6 (18.0–87.7) |
Group | Overall survival | Progression-free survival | ||
---|---|---|---|---|
HR (95 % CI) |
p value | HR (95 % CI) |
p value | |
Response to induction chemotherapy | ||||
Primary refractorinessa vs ≥PR | 3.21 (1.17–8.79) | 0.023 | 4.56 (1.86–11.19) | 0.001 |
Marrow involvement at diagnosis | ||||
Yes vs no | 3.85 (1.51–9.78) | 0.005 | 3.58 (1.55–8.27) | 0.003 |
Performance of risk models in prediction of outcome after autoHCT
Risk model | Risk group stratification | 5-year OS (95 % CI) | HR (95 % CI) |
p value | 5-year PFS (95 % CI) | HR (95 % CI) |
p value |
---|---|---|---|---|---|---|---|
IPI | Low (score 0–1) | 77.9 (51.2–92.2) | 1 | 0.12 | 74.5 (49.8–89.6) | 1 | 0.23 |
Int-1 (score 2) | 27.3 (8.3–60.8) | 3.90 (1.03–14.8) | 0.046 | 28.5 (9.3–60.7) | 2.76 (0.85–9.03) | 0.09 | |
Int-2 and high (score 3–5) | 53.1 (30.9–74.1) | 2.16 (0.58–8.0) | 0.25 | 51.1 (31.3–70.6) | 2.29 (0.72–6.94) | 0.17 | |
PIT | Low (score 0) | 88.9 (56.4–98.0) | 1 | 0.036 | 90.0 (59.5–98.2) | 1 | 0.059 |
Low–int (score 1) | 57.4 (30.4–80.6) | 3.73 (0.45–31.13) | 0.22 | 51.8 (28.6–74.3) | 5.21 (0.66–41.31) | 0.118 | |
Int and high (score 2–3) | 31.8 (7.7–55.9) | 9.27 (1.19–72.11) | 0.033 | 32.4 (15.3–55.9) | 9.52 (1.23–73.51) | 0.031 | |
Simplified two-class PIT | Score 0–1 | 70.0 (50.0–90.0) | 1 | 65.4 (47.0–83.8) | 1 | ||
Score 2–3 | 31.8 (7.7–55.9) | 3.45 (1.33–8.91) | 0.011 | 32.4 (15.3–55.9) | 2.59 (1.12–6.01) | 0.027 |